CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENP1), is an integral membrane glycoprotein that acts as an extracellular nucleotide-hydrolyzing enzyme. CD39 inhibits ADP-induced platelet aggregation by hydrolyzing ADP to AMP, and ultimately generating Adenosine. Intracellular CD39 undergoes glycosylation at six N-glycosylation sites and translocates to the membrane in order to be an active enzyme. Alternative splicing gives rise to three CD39 isoforms, vascular, placenta I and placenta II. The placenta I isoform differs at the amino terminus whereas the placenta II isoform is missing amino acids 300-510 at the C-terminus. CD39 is expressed in vascular tissues including placenta, lung, skeletal muscle and kidney, as well as endothelium, smooth muscle, cardiac cells, lymphocytes, such as activated B cells, activated NK cells, macrophages, Dendridic cells and platelets. CD39 may be used as an anti-thrombic agent for pre-treating patients at risk for coronary artery occlusion and thrombic stroke.
200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.
Antibody Type:
Recombinant Monoclonal Antibody
Application Notes:
Immunohistochemistry (Formalin-fixed) (1-2ug/ml for 30 minutes at RT),(Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes),Optimal dilutio
Formalin-fixed, paraffin-embedded human tonsil stained with CD39 Recombinant Rabbit Monoclonal Antibody (CD39/8538R). Inset: PBS instead of primary antibody, secondary only negative control.
